semaglutide affirm Semaglutide GLP-1 Receptor Agonist Research

High obesity prevalence, expanding cardiovascular indications, recent oral formulation approvals, and intensifying competition between semaglutide and tirzepatide are supporting U.S

doi: 10.1038/srep25288 86 PrcigoutP.-A.ClaessenD.MakowskiD.RobertC

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

GLP-1 Peptide Medications GLP-1 peptides -- such as semaglutide and tirzepatide -- may be a more clinically validated option for patients whose primary goal is meaningful weight loss, and these are addressed in separate articles in this Peptide Series

Do not dismiss symptoms assuming they are normal supplement side effects

In June 2023, The New England Journal of Medicine published Eli Lilly and Company's Phase 2 clinical trial data on Retatrutide (LY3437943) online